| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
UCM-05 targets fatty acid synthase (FASN), a key enzyme in the de novo synthesis of long-chain fatty acids. FASN is overexpressed in numerous cancers and has been linked to tumor progression, aggressiveness, and poor prognosis. UCM-05 also targets FtsZ (filamentous temperature-sensitive protein Z), a protein essential for bacterial cell division. By inhibiting FASN, the compound disrupts lipid metabolism in cancer cells, leading to reduced proliferation and increased apoptosis.
|
|---|---|
| ln Vitro |
UCM-05 is a potent FASN inhibitor with activity against HER2+ breast cancer and activity in anti-HER2-resistant cell lines. It has a molecular weight of 464.38 g/mol and formula C24H16O10. The compound also inhibits FtsZ, a protein essential for bacterial cell division, with a MIC value of 100 μM against Bacillus subtilis, but lacks activity against Gram-negative E. coli. UCM-05 inhibits FASN-mediated enzymatic synthesis of de novo long-chain fatty acids.
|
| ln Vivo |
In vivo activity data for UCM-05 are not extensively detailed, but the compound has shown activity against HER2+ breast cancer in preclinical models. As a FASN inhibitor, it is expected to exhibit antitumor activity in vivo by disrupting lipid metabolism in cancer cells. The compound's activity in anti-HER2-resistant cell lines suggests potential for overcoming drug resistance. Specific in vivo efficacy studies and animal model data are not specified in the public domain.
|
| Enzyme Assay |
The in vitro enzyme assay for UCM-05 typically involves measuring the inhibition of FASN enzymatic activity. FASN enzyme is incubated with varying concentrations of UCM-05 (typically 0.001-100 μM) in the presence of substrates (acetyl-CoA, malonyl-CoA, and NADPH). The enzymatic activity is measured by monitoring the oxidation of NADPH spectrophotometrically at 340 nm. The IC50 value is determined by plotting the percentage of inhibition against compound concentration. The compound is dissolved in DMSO and diluted in assay buffer.
|
| Cell Assay |
In vitro cellular assays for UCM-05 typically involve treating HER2+ breast cancer cell lines with the compound at concentrations ranging from 0.001 to 10 μM for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or CellTier-Glo assays. Lipid synthesis is assessed by measuring fatty acid incorporation using radiolabeled acetate. Cell cycle distribution and apoptosis are analyzed by flow cytometry. The compound is dissolved in DMSO as a stock solution and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for UCM-05 are not extensively documented. For potential in vivo applications, the compound could be administered to mice via oral gavage or intraperitoneal injection at doses determined from preliminary studies. HER2+ breast cancer xenograft models could be used to evaluate antitumor efficacy. Tumor growth is monitored by caliper measurements. Lipid metabolism and FASN activity in tumors would be assessed. The compound's pharmacokinetics and pharmacodynamics would be evaluated in these models.
|
| ADME/Pharmacokinetics |
UCM-05 has a molecular weight of 464.38 g/mol and formula C24H16O10. It has a purity of ≥98%. Recommended storage is at -20°C. The compound is soluble in DMSO and other organic solvents. Detailed PK parameters such as half-life, Cmax, AUC, and bioavailability would require experimental determination. The compound's molecular weight and structural features suggest it may have moderate oral bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicity data for UCM-05 are not extensively reported. The compound is intended for research use only and is not approved for human therapeutic applications. Standard preclinical toxicity assessments would include acute toxicity studies in rodents, repeated-dose toxicity studies, and assessment of off-target effects. As a FASN inhibitor, the compound may affect normal lipid metabolism, which could contribute to potential toxicity. Appropriate safety precautions should be taken when handling.
|
| References | |
| Additional Infomation |
UCM-05 (CAS 1094451-90-7) is a potent and selective small-molecule inhibitor of fatty acid synthase (FASN). It has a molecular weight of 464.38 g/mol and formula C24H16O10. UCM-05 exhibits activity against HER2+ breast cancer and activity in anti-HER2-resistant cell lines. It also inhibits FtsZ and Gram-positive bacteria such as B. subtilis with a MIC of 100 μM. The compound is also known as G28UCM. It is not approved for clinical use.
|
| Exact Mass |
464.074
|
|---|---|
| CAS # |
1094451-90-7
|
| PubChem CID |
24896615
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
895.1±65.0 °C at 760 mmHg
|
| Flash Point |
313.3±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.787
|
| LogP |
4.63
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
34
|
| Complexity |
707
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C=C(C=C2OC(=O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
|
| InChi Key |
KJCWIWDPTNVWRX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H16O10/c25-16-6-12(7-17(26)21(16)29)23(31)33-14-5-11-3-1-2-4-15(11)20(10-14)34-24(32)13-8-18(27)22(30)19(28)9-13/h1-10,25-30H
|
| Chemical Name |
[4-(3,4,5-trihydroxybenzoyl)oxynaphthalen-2-yl] 3,4,5-trihydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~215.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
